Consano Bio

Transforming the Standard of Care in Painful & Debilitating Orthopedic Conditions

[Consano Bio @Consano_Bio]

Full transcript available here:
https://t.co/EIrg3lTWk8

[Consano Bio @Consano_Bio]

Just out! Thanks to @KarenJagoda of #EmpoweredPatientPodcast for speaking with our CEO Andrew Hall @Consano_Bio

Listen here: Disease-Modifying Allogeneic Treatment for Chronic Sciatica with Andrew Hall Consano Bio

https://t.co/b9HIudiUff

#ConsanoBIo #Sciatica #BackPain

[Consano Bio @Consano_Bio]

Key findings include:
• Demonstrated immunomodulatory activity in vitro
• Downregulated inflammatory and upregulated cell growth pathways in vitro
• Reduced neuropathic pain and inflammation of nerve cells in vivo

Read the peer-reviewed article here:
https://t.co/YyqP0bab93

[Consano Bio @Consano_Bio]

Congratulations to the @Consano_Bio team and collaborators on this important publication!
https://t.co/DcXDcdvGDp

#Sciatica #Biotechnology #Bioengineering #BackPain #NonOpioids #Opioids

[Consano Bio @Consano_Bio]

Congratulations to the @Consano_Bio team and collaborators on this important publication!
https://t.co/DcXDcdvGDp

#Sciatica #Biotechnology #Bioengineering #BackPain #NonOpioids #Opioids

[Consano Bio @Consano_Bio]

From @Consano_Bio's COO & Head of R&D, Jennifer Schmitke, PhD in today's release announcing a peer-reviewed publication supporting the therapeutic potential of C-1101 in chronic, painful lumbosacral radiculopathy (LSR) or chronic sciatica
Read here:
https://t.co/DcXDcdvGDp

[Consano Bio @Consano_Bio]

Thank you to our dedicated research team and academic collaborators for advancing our understanding of C-1101, a potentially first-of-its-kind therapy for chronic sciatica. Check out our announcement here:
https://t.co/NbtzaWtNK2

[Consano Bio @Consano_Bio]

Huge publication news from @Consano_Bio!

We are proud to share our latest peer-reviewed study published in @FrontBioeng: "C-1101 multi-protein platelet and plasma-derived therapeutic to treat chronic lumbosacral radiculopathy.”

https://t.co/YyqP0bab93

[Consano Bio @Consano_Bio]

ICYMI - Coverage of our recent news in BioPharm International - FDA Grants Fast Track Designation to Consano Bio's Platelet-Derived Biologic C-1101 for Chronic Sciatica #Sciatica #ChronicPain #PainMeds #NonOpioid #FastTrack #biotech
https://t.co/yAxRgoHAoz

[Consano Bio @Consano_Bio]

Thanks to @pharmacally for covering our recent news:
Consano Bio’s C-1101 Wins FDA Fast Track for Chronic Sciatica
https://t.co/iJbBTtZePD
#Sciatica #ChronicPain #PainMeds #NonOpioid #FastTrack #biotech

[Consano Bio @Consano_Bio]

Thanks to BioPharm International for covering today's update:
FDA Grants Fast Track Designation to Consano Bio's Platelet-Derived Biologic C-1101 for Chronic Sciatica
https://t.co/yAxRgoHAoz

#Sciatica #ChronicPain #PainMeds #NonOpioid #FastTrack #biotech

[Consano Bio @Consano_Bio]

“Fast Track Designation underscores the significant unmet need in #ChronicSciatica, a serious and debilitating condition. C-1101 is designed to address the underlying biology of nerve injury rather than simply manage #pain."
Full release here:
https://t.co/ggZKfaLaxX

[Consano Bio @Consano_Bio]

Update! @Consano_Bio Receives FDA Fast Track Designation for C-1101 in Chronic, Painful Lumbosacral Radiculopathy (LSR) or Chronic Sciatica
https://t.co/Q5CWwGhJAE
#Sciatica #ChronicPain #PainMeds #FastTrack #biotech

[Consano Bio @Consano_Bio]

Thanks to @PharmExec for covering this week's news:

FDA Clears Consano’s IND for C-1101
https://t.co/zOgkHO8mzx

#Biotech #NonOpioids #BackPain #Sciatica #INDClearance

[Consano Bio @Consano_Bio]

CEO Andrew Hall in today's release - @Consano_Bio Receives FDA Investigational New Drug Clearance to Expand the C-1101 Chronic Sciatica Clinical Development Program into the US

https://t.co/ErZJshv6lS

[Consano Bio @Consano_Bio]

@Consano_Bio Receives FDA Investigational New Drug Clearance to Expand the C-1101 Chronic Sciatica Clinical Development Program into the United States

https://t.co/ErZJshuywk

#Biotech #NonOpioids #BackPain #Sciatica #INDClearance

[Consano Bio @Consano_Bio]

#BackPain including lumbosacral radiculopathy (LSR) aka chronic #sciatica is the #1 cause of disability in the US for the past 3 decades. Despite its prevalence, there are no FDA-approved treatments. More here: https://t.co/yL5FLDdKHx

#NonOpioids #Biotech

From our SAB member:

[Consano Bio @Consano_Bio]

"Chronic sciatica represents one of the largest unmet needs in the U.S."

More from Andrew Hall, Chief Executive Officer of Consano Bio, in today's announcement.

#Biotech #NonOpioids #BackPain #Sciatica

[Consano Bio @Consano_Bio]

As Consano Bio advances C-1101 through clinical development as a potential first-in-class, non-opioid therapy for chronic sciatica, we're proud to highlight the distinguished experts who comprise our Scientific Advisory Board.

Read today's announcement: https://t.co/yi6kerx44F

[Consano Bio @Consano_Bio]

Check out the latest #Bench2Bedside featuring @Consano_Bio - Targeting the Root of Pain: A New Era for Chronic #Sciatica Therapeutics

https://t.co/DDWe8y1eAc

#Biotech #NonOpioids #BackPain

[Consano Bio @Consano_Bio]

Next Stop: San Diego - Our team will be attending the BIO International Convention and looks forward to connecting with potential partners, collaborators, and investors to discuss recent corporate achievements and upcoming catalysts.

#BIO2026 #Biotech #NonOpioids #BackPain